What is Wilson Wolf?
Wilson Wolf Manufacturing is at the forefront of cell therapy innovation, specializing in advanced manufacturing solutions. Their proprietary G-Rex technology is engineered to optimize T cell therapy and routine cell culture, offering a substantial upgrade over conventional perfusion and mixing systems. By enhancing the efficiency and efficacy of cell manufacturing, Wilson Wolf aims to directly impact cancer patient care and support the broader field of cell therapy research and development.
How much funding has Wilson Wolf raised?
Wilson Wolf has raised a total of $257.4M across 2 funding rounds:
Debt
$350K
Stock Offering
$257M
Debt (2020): $350K with participation from PPP
Stock Issuance/Offering (2023): $257M led by Bio-Techne
Key Investors in Wilson Wolf
Bio-Techne
Bio-Techne Corporation, a global life sciences company established in 1981, provides essential tools and reagents for research and diagnostics, aiding in the investigation of biological processes and disease progression, as well as drug discovery and clinical testing.
PPP
Public-Private Partnership
What's next for Wilson Wolf?
The substantial enterprise-level funding, particularly the recent strategic investment, positions Wilson Wolf for accelerated growth and market expansion. This capital infusion is expected to fuel further development of their G-Rex technology, scale manufacturing capabilities, and potentially broaden their reach within the healthcare and research sectors. The company's focus on improving cell therapy processes suggests a strategic direction towards becoming a key enabler in the burgeoning field of personalized medicine and advanced cancer treatments.
See full Wilson Wolf company page
